SFM
UTHR icon

Soros Fund Management’s United Therapeutics UTHR Stock Holding History

Soros Fund Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,054
Closed -$242K – 229
2024
Q1 		$242K Buy
+1,054
New +$238K ﹤0.01% 193
2016
Q1 		– Sell
-4,400
Closed -$689K – 309
2015
Q4 		$689K Buy
+4,400
New +$641K 0.01% 174

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Soros Fund Management's UTHR Position: Q2 2024 in Review

Soros Fund Management sold out of United Therapeutics (UTHR) in Q2 2024, closing a stake of 1,054 shares — an estimated $242K sold.

Soros Fund Management first reported a position in UTHR in Q4 2015 and held it in 2 quarters. The position peaked at $689K in Q4 2015. 566 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

  • Soros Fund Management reported no remaining United Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Soros Fund Management sold 1,054 United Therapeutics shares in Q2 2024, an estimated $242K.
  • Soros Fund Management first reported a position in United Therapeutics in Q4 2015 and held it in 2 quarters.
  • Soros Fund Management's United Therapeutics position peaked at $689K in Q4 2015.
  • 566 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Soros Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.